Formistin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Formistin

Quick Facts

Property Description
Active ingredient Cetirizine Dihydrochloride
Form Tablet, oral solution, drops, syrup (Oral administration)
Pharmacological class H1-receptor antagonist
Common use Systemic relief of general allergic symptoms
Origin Synthetic, derived from Hydroxyzine

Formistin is the commercial designation for a medicinal product containing the active substance Cetirizine Dihydrochloride, which is pharmacologically classified as a non-sedating second-generation antihistamine. Its primary function is to provide systemic relief from the discomfort caused by general allergic reactions by modulating the body's response to histamine release.

What Type of Medicine is Formistin?

Formistin belongs to the class of H1-receptor antagonists, which means its core action is targeted at blocking specific receptors that mediate allergic symptoms. The drug is a synthetic compound that is chemically derived as a carboxy-metabolite of the first-generation antihistamine Hydroxyzine. This classification as a second-generation antihistamine is significant because it indicates a high selectivity for peripheral H1 receptors, which is clinically recognized for contributing to a more focused effect on the immune system compared to older compounds. This means the drug focuses its action primarily on the allergic response outside of the central nervous system, addressing common discomforts associated with exposure to seasonal allergens.

Composition, Forms, and General Purpose

The medication is a single-component product whose identity is defined by the sole active ingredient, Cetirizine Dihydrochloride. Formistin is supplied for oral administration in various dosage forms, predominantly as tablets utilizing solid excipients, and also as an oral solution or drops, which rely on an aqueous vehicle. This range of presentations facilitates different user groups, with the liquid forms often positioned for patient groups requiring flexibility in dose administration. By operating through selective peripheral H1-receptor blockade and preventing histamine from binding, the drug's general purpose is to provide relief by reducing the physical manifestations of the allergic cascade, such as reducing itching and swelling. Various presentations including oral solution and tablet forms are available to support flexible use based on user needs.

What side effects are possible with Formistin?

Possible Side Effects and Safety Information

The safety profile of Formistin (Cetirizine Dihydrochloride) is characterized by classifying adverse reactions based on their frequency and the physiological system affected, according to official regulatory documentation.


Official Adverse Reaction Categories

Adverse effects are categorized by frequency, following regulatory conventions:

  • Common (affects less than 1 in 10 people): Reactions frequently reported include somnolence (drowsiness), fatigue, headache, and dry mouth.
  • Uncommon (affects less than 1 in 100 people): Includes agitation, pruritus (itching), and rash.
  • Rare (affects less than 1 in 1,000 people): Includes hypersensitivity reactions, convulsions, tachycardia (fast heart rate), urticaria, and abnormal hepatic function (elevated enzymes/bilirubin).
  • Very Rare (affects less than 1 in 10,000 people): Includes serious reactions such as anaphylactic shock and oculogyric crisis.

Safety Considerations and Restrictions

The official labeling documents specific safety constraints, particularly for certain patient populations:

  • Impaired Organ Function: Specific caution and dosage modification are noted for patients with renal impairment or hepatic impairment due to the drug's altered clearance in these groups. The same considerations apply to older adults due to typically diminished renal function.
  • Predisposed Patients: Caution is recommended in patients with epilepsy and those at risk of convulsions. The potential for urinary retention is also noted, particularly in individuals with pre-existing conditions (e.g., prostatic hyperplasia).
  • Exposure-Related Patterns: Regulatory documents note the potential for severe, generalized pruritus (itching) as a rare event occurring upon cessation after long-term daily use.

These classifications define the risk spectrum, focusing on common, generally non-serious effects, while explicitly documenting the low incidence of rare but significant systemic events.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Formistin overdose is based on documented clinical manifestations observed, particularly following ingestion of at least five times the recommended daily dose. Signs include significant CNS effects such as somnolence, profound sedation, dizziness, confusion, tremor, and potentially severe outcomes like stupor. The drug's profile also encompasses signs consistent with possible anticholinergic activity, which may manifest as mydriasis (pupillary dilation) or urinary retention, alongside the cardiovascular effect of tachycardia (rapid heart rate).

For individuals with suspected overdose, government-mandated instructions require that emergency medical attention be sought immediately, or that a Poison Control Center be contacted at once. Urgent emergency services must be contacted if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Management is constrained by the official finding that no specific antidote is known for cetirizine; therefore, clinical care must be strictly symptomatic and supportive, noting that the substance is not effectively removed by dialysis. Overdose presentations in pediatric populations, specifically infants, may involve initial restlessness and irritability followed by drowsiness.

Therapeutic Uses of Formistin

What Formistin Treats: Main Uses and Benefits

Formistin is commonly used to provide systemic symptomatic relief for conditions associated with heightened physiological activity, primarily seasonal allergic rhinitis (hay fever) and perennial (year-round) allergies. The medication generally helps address symptom clusters that may become intense or disruptive, including sneezing, a runny nose (rhinorrhea), and itching of the nasal passages and throat, along with associated tearing and itching of the eyes (allergic conjunctivitis). It is considered relevant for managing symptoms that interfere with daily comfort during periods of allergen exposure.

The core indications for which it is commonly used include allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria (hives). The medication is also applied in conditions involving distressing allergic skin manifestations, such as skin itching (pruritus). It provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods. The medication is applied in scenarios where additional management of discomfort is required, especially during flare-ups. This assists with maintaining a sense of stability when symptoms may intensify temporarily.


QuickFact Block

Quick Fact: Relief for Allergic Symptoms
Primary Focus Seasonal and perennial allergic rhinitis
Skin Conditions Chronic hives and generalized skin itching (pruritus)
Symptom Easing Nasal discharge, sneezing, itchy eyes, and skin wheals
Patient Benefit Supports easing distress and contributes to improved day-to-day comfort

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Formistin (Cetirizine Dihydrochloride) eligibility is defined by age, organ function, and specific medical conditions, as specified in regulatory labeling. The medicine is contraindicated (prohibited) for patients with a known hypersensitivity to cetirizine, hydroxyzine, or any piperazine derivatives. It is also strictly prohibited for patients with severe renal impairment (CLcr < 10 mL/min) because the drug is primarily cleared by the kidneys.

Population Group Eligibility Status (Regulatory Basis)
Age 12 and Older Eligible for standard use.
Children 6 to 11 years Eligible for use, generally with tablets or liquid forms.
Children under 6 years Not recommended for film-coated tablet formulation due to dosing difficulties; liquid forms are permitted at specific ages for certain indications.
Moderate Renal Impairment Restricted use; a reduced dosage is required and must be individualized based on kidney function (CLcr) [EMA SmPC 4.2].
Pregnancy/Lactation Use discouraged; should only be used if clearly needed, as the drug is excreted into human breast milk [UK SmPC 3.4].
Urinary Retention Factors Caution is recommended for patients with predisposition factors such as prostatic hyperplasia [EMA SmPC 4.4].

Eligibility also requires caution for patients with epilepsy or those at risk of convulsions. Older adults typically do not require dose adjustment provided their renal function remains normal.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Formistin (Cetirizine Dihydrochloride) is structured around documented pharmacokinetic and pharmacodynamic interactions that affect the drug's exposure and central nervous system (CNS) performance.

Interaction Type Interacting Substance/Condition Regulatory Outcome
Pharmacokinetic Theophylline (400 mg once daily) Co-administration causes a formal 16% decrease in Formistin clearance, resulting in increased systemic exposure (AUC).
Pharmacodynamic Alcohol (Ethanol), CNS Depressants (e.g., opioids, sedatives) Results in an additive CNS depressant effect, leading to further reduction in alertness and impairment of performance.
Transporter-Mediated P-glycoprotein (P-gp) Inhibitors Formistin is a documented P-gp substrate; co-administration may potentially increase systemic exposure of the active substance.
Drug-Food Food Does not alter the extent of absorption (AUC), but formally reduces the rate of absorption (Cmax is decreased and Tmax is delayed).

Restrictions against concurrent use are documented for alcohol and other CNS depressants due to the risk of additive central effects. Additionally, official labeling includes a population-dependent consideration: patients with renal or hepatic impairment have a potential risk of increased systemic exposure and adverse effects due to the resulting decreased drug clearance. These regulatory statements establish the necessary interaction constraints without offering clinical interpretation or treatment recommendations.

Mechanism of Action

Peripheral H1-Receptor Blockade

Formistin acts as a high-affinity selective antagonist primarily targeting peripheral Histamine H1-receptors, preventing the binding and subsequent activation by released histamine. This molecular interaction initiates a mechanistic cascade that reduces histamine-induced increases in vascular permeability and local tissue vasodilation. The molecule exhibits limited ability to cross the blood-brain barrier, which focuses its action on the peripheral nervous system and associated tissues.

Modulation of Inflammatory Cell Activity

The molecule engages secondary mechanisms that modulate downstream inflammatory processes through non- H1 pathways. It specifically causes the inhibition of chemotaxis (recruitment) of specific inflammatory cells, such as eosinophils, to inflammation sites. This activity limits the release of additional inflammatory mediators, resulting in the modulation of the late-phase inflammatory response.

Reduced Microvascular Dynamics

The combined H1-receptor blockade and inhibition of inflammatory cell migration results in specific changes within the microvascular system. This mechanism reduces the abnormal fluid extravasation and blood vessel dilation that contribute to the formation of wheal and flare reactions.

Dosage and Administration Information

Formistin is administered for systemic use primarily via the oral route, utilizing available dosage forms such as tablets, oral solutions, and drops. An intravenous (IV) formulation is also available for specific acute use, administered in a controlled clinical environment.


The standard administration pattern for adults is 10 milligrams (mg) taken once daily. For managing milder symptoms or as an initial regimen, some patients may use a lower starting dose of 5 mg once per day. The maximum dosage is restricted to 10 mg in any 24-hour period. Oral administration provides flexibility as the dose may be taken with or without food.


Administration over time may involve either intermittent use for acute symptomatic periods or continuous daily use for the management of chronic conditions. A key procedural requirement involves dose modification in patients with impaired renal function; for example, those with moderate kidney impairment often require a reduction to 5 mg once daily due to the drug’s elimination pathway. For the intravenous route, the solution is administered undiluted as a slow IV push over a period of one to two minutes. If a routine oral dose is missed, the recommended procedural step is to omit the missed dose and resume the normal once-daily schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Formistin (Cetirizine)


Evidence for Use in Seasonal and Perennial Allergic Rhinitis (SAR/PAR)

The primary research for Formistin in conditions such as hay fever and year-round allergies has used short-term, randomized controlled trials (RCTs). These studies are designed to compare the drug's effect to a placebo (an inactive substance) over defined time intervals. Researchers have applied this design in research exploring how symptoms change over time, particularly those related to the physical discomfort of nasal discharge, sneezing, and itchy eyes. Trials also used controlled allergen exposure models to see how quickly a change in measured symptoms was observed when patients were exposed to a known allergen. Findings describe patterns observed in the studies where changes in symptoms were measured in the observed populations in the short-term settings evaluated. Data show patterns related to symptom change but do not determine whether an individual will respond similarly in an uncontrolled setting.

Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Formistin was evaluated in studies focusing on chronic hives, a condition presenting with cycles of stability and flare-ups. Research explored the drug’s use in conditions characterized by physical discomfort, specifically targeting the outcomes related to weal (hive) size, count, and itching (pruritus) severity. Research describes how skin symptoms were measured in the observed populations over short-term periods. Studies monitored outcomes capturing phases of heightened symptom activity. Sample sizes were modest in some of the studies focusing on higher dosages, meaning evidence quality varies across studies.

Long-Term Evidence and Follow-up

While many initial trials focused on short-term symptom measurement, some research has explored the long-term use of Formistin and documented observations. For chronic conditions, observations are available through open-label safety extensions, which contribute to the body of evidence. This data show patterns related to persistence of effect over time, but the certainty remains low compared to a dedicated, controlled, long-term RCT.

Evidence in Special Populations

Formistin was studied for use in diverse age groups, including both adults and children. Research suggests that specific study designs have limitations, particularly for older adults (age 65 and above), where limited information for long-term outcomes is available compared to younger adult groups. Studies for Formistin in pregnant women are not widely available, meaning evidence is limited for this population.

Key Studies & References

  1. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit
  2. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects (Focus on Safety/Pediatric Data)

Frequently Asked Questions (FAQ)

Common questions about Formistin (FAQ)

Q: What is the main difference between Formistin and other non-drowsy allergy medicines?

Formistin is officially classified as a second-generation H1-receptor antagonist (antihistamine). Regulatory descriptions indicate that it is highly selective for peripheral receptors, which are the main targets for allergy relief. This high selectivity is documented as contributing to its generally limited effects on the central nervous system compared to older classes of antihistamines.

Q: How quickly does Formistin start to work?

According to pharmacokinetic data found in official product information, the onset of action is generally described as occurring within one hour for the oral solution in studies. For the tablet formulation, the time it takes for the drug to begin its effects may be slightly longer.

Q: Can I take Formistin if I have kidney issues?

Official labeling addresses the use of Formistin in patients with kidney issues because the drug is primarily cleared by the kidneys. Individuals diagnosed with severe renal impairment are contraindicated (prohibited) from using Formistin. For patients with moderate renal impairment, regulatory guidelines note that the medicine may require a dosage adjustment due to the drug’s altered clearance.

Q: Is Formistin approved for use during pregnancy in some countries?

Official regulatory documents describe the use of Formistin during pregnancy as discouraged. The prescribing information states that it should only be administered if a clear, defined need has been established. Official documentation states that the active substance has been found to be excreted into human breast milk.

Q: Does Formistin help with stuffy nose, or only with sneezing and itching?

Regulatory documents list Formistin's use for the relief of general symptoms associated with allergic rhinitis, including nasal discharge, sneezing, and ocular (eye) symptoms. The mechanism of action is described in terms of reducing the effects of histamine release. The drug's action is intended to reduce these common allergic discomforts.

Q: Is there a generic version of Formistin available?

The active ingredient in Formistin is Cetirizine Dihydrochloride. The generic status of Cetirizine Dihydrochloride is publicly documented in regulatory listings, confirming that generic versions of the medicine are available in many regions.

Q: Do studies support the use of Formistin for chronic hives?

Yes, official research overviews indicate that Formistin was evaluated in short-term studies for the treatment of symptoms associated with Chronic Idiopathic Urticaria (CIU), commonly known as chronic hives. These studies focused on measurable outcomes related to weal size, count, and itching severity.

Q: What should I do if I experience a rare but serious side effect listed for Formistin?

Official safety documents describe the procedure for rare or very rare reactions, particularly signs of a severe hypersensitivity or an anaphylactic shock, as stopping the medication. The guidance advises seeking immediate medical attention for any signs of a severe reaction.

Q: Is Formistin effective year-round, or only during allergy season?

Regulatory documents indicate that Formistin is approved for use in both Seasonal Allergic Rhinitis (SAR, commonly referred to as hay fever) and Perennial Allergic Rhinitis (PAR). Perennial use refers to the management of year-round allergies.

Q: Why is Formistin not recommended for infants in some official sources?

For children under 6 years of age, the film-coated tablet formulation of Formistin is officially not recommended. Regulatory guides explain that this is due to factors such as dosing difficulties associated with the tablet format. Liquid forms are permitted for specific indications and age groups.

Q: Does the efficacy of Formistin decrease over time with regular use?

While the certainty remains low compared to dedicated controlled trials, longer-term research has generated observations related to the persistence of the effect over time. These observations contribute to the body of evidence on the long-term use of the medicine.

Q: Can Formistin cause heart palpitations?

Official safety listings for Formistin include tachycardia (fast heart rate) as a rare adverse reaction, meaning it affects less than 1 in 1,000 people. Irregular or fast heart rates are noted as reactions reported in the drug's safety profile.

Q: Does Formistin affect liver function tests?

Regulatory safety documents note that abnormal hepatic function (liver function) is a rare adverse reaction observed in patients using Formistin. This includes elevations in liver enzymes and bilirubin, which are markers typically measured in liver function tests.

Q: Is there a risk of dependency or withdrawal with Formistin?

Official safety information documents reports of severe, generalized pruritus (itching) as a rare event. This event is noted to occur upon cessation of the medicine after periods of long-term daily use.

Q: What kind of studies have been performed on Formistin's long-term safety?

Research overviews indicate that long-term safety information has been collected primarily through open-label safety extensions of initial trials. This type of study provides observational data on persistence of effect and safety for patients using the medicine for chronic conditions.

Q: Does Formistin interact with psychiatric medications?

Regulatory documents state that Formistin should be used with caution when co-administered with other CNS depressants. This classification includes medications like certain sedatives or opioids, due to the risk of an additive depressant effect on the central nervous system.

Q: Are certain populations, like the elderly, more likely to experience side effects from Formistin?

Official safety considerations recommend caution for older adults as a population of focus. This is because older adults typically have diminished renal function, which can result in the potential for increased systemic exposure and adverse effects due to the drug's altered clearance pathway.

Q: Are there different strengths of Formistin tablets?

Dosing instructions for Formistin are typically described using a standard adult daily dose of 10 mg and sometimes a lower starting dose of 5 mg. The availability of different strengths is implied by the official guidance, which includes instructions for both a standard dose and a lower starting dose.

How should Formistin be stored and disposed of?

How to Store and Dispose of Formistin

Official regulatory guidelines define specific conditions for storing and disposing of Formistin (Cetirizine Dihydrochloride) to maintain product stability and ensure environmental safety.


Storage Requirements

Formistin must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from high humidity and excessive heat. Containers should be kept tightly closed and the product must not be used if the package, such as a blister unit or seal, is broken. It is a mandatory requirement to keep Formistin out of the sight and reach of children.

Disposal Instructions

Expired or unused Formistin must not be disposed of in household waste or flushed down the toilet, as this can contaminate water sources. Disposal must occur through an approved method, such as taking the product to a pharmacist or a designated collection point, in accordance with all local and national regulations for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Formistin found in:

A-Z Index: